Abstract

Hengan International Group Co., Ltd. is scheduled to report quarterly results after-market on August 19, 2026; current market expectations point to modest year-over-year revenue growth and a stable profit profile, with attention centered on margin resilience and earnings quality in light of recent gross margin levels.

Market Forecast

Based on the latest market consensus, Hengan International Group Co., Ltd.’s current-quarter revenue is projected at RMB 11.54 billion, up 1.51% year over year. Public forecasts for gross profit margin, net profit margin, and adjusted EPS for the quarter are not available at this time.

The main business is expected to emphasize disciplined pricing and product-mix management to defend margins while sustaining top-line stability amid normalizing promotions and channel inventory. The most promising segment by growth potential remains Hygiene Products, supported by ongoing product upgrades and mix shifts; in the latest reported breakdown, this segment generated RMB 6.86 billion, while segment-level YoY was not disclosed.

Last Quarter Review

In the previous quarter, Hengan International Group Co., Ltd. delivered revenue of RMB 11.26 billion (+3.94% YoY), a gross profit margin of 35.47%, GAAP net profit attributable to the parent company of RMB 581.00 million, a net profit margin of 10.32%, and adjusted EPS was not disclosed by the company; quarter-on-quarter net profit growth was effectively flat.

A key financial highlight was EBIT of RMB 1.73 billion, representing 18.38% year-over-year growth, reflecting operating leverage and cost control that outpaced the top-line. By business line in the latest disclosure, Tissue Products contributed RMB 15.27 billion and Hygiene Products RMB 6.86 billion (Other RMB 3.46 billion; intersegment eliminations RMB -2.52 billion); segment-level YoY changes were not provided.

Current Quarter Outlook

Main business: Tissue Products

Tissue Products is expected to be the principal earnings anchor this quarter, with investors watching how pricing discipline and input-cost dynamics translate into gross profit margin relative to last quarter’s 35.47%. Pulp remains a meaningful cost driver for tissue manufacturing; the interplay between contract and spot pulp costs and inventory hedging will likely determine if gross spread can be maintained despite muted pricing power in mass channels. On the revenue side, the company’s focus on tiered product portfolios and promotional rationalization should support stable volume without sacrificing unit economics, which is essential to protecting the 10.32% net profit margin baseline seen last quarter. If price-mix modestly tilts toward mid-to-premium SKUs, incremental margin benefits may offset any seasonal volume fluctuations, helping EBIT performance track closer to the RMB 1.73 billion momentum achieved last quarter.

Channel execution is a second major swing factor. After a period of normalization in offline and e-commerce channels, sustainable replenishment rather than bulk promotions should improve revenue quality and cash conversion. For tissue, shelf availability and on-platform search conversion drive near-term sell-through; if inventory levels remain balanced, sell-in and sell-out should align, reducing the likelihood of margin-dilutive promotional spending. Given last quarter’s quarter-on-quarter net profit stability, investors may treat any sequential improvement in tissue gross spread as a positive surprise, while a deterioration could quickly weigh on sentiment.

Finally, operating expense discipline will be closely watched. With scale benefits and prior initiatives already visible in the 18.38% YoY EBIT increase last quarter, management’s cost control in selling and logistics lines will be scrutinized against revenue growth of only 3.94% YoY in the previous quarter and 1.51% YoY projected for the current quarter. Sustaining a balanced cost base while maintaining brand support should help defend both the reported net margin and the quality of earnings.

Most promising business: Hygiene Products

Hygiene Products offers the clearest path for incremental mix-driven growth in the current quarter, as product upgrades and innovation in core SKUs can deliver revenue lift without heavy discounting. The segment’s contribution, last disclosed at RMB 6.86 billion, underscores its scale to influence consolidated margin if premium lines capture a larger share of the portfolio. While segment-level YoY data were not disclosed, the trajectory of EBIT and gross profit last quarter indicates that higher-margin categories can provide a buffer if tissue volumes are steady rather than brisk.

Execution in e-commerce and specialty retail is crucial for hygiene, where brand differentiation and feature-led marketing convert into higher average selling prices. A constructive setup would include sustained momentum in online channels and better in-store placement for new SKUs, enabling the company to lean less on short-term promotions and preserve value over volume. Additionally, product development that emphasizes comfort, durability, and specialized use cases can broaden the addressable base and increase repurchase rates, supporting steady top-line gains even if overall revenue growth for the group is in the low single digits.

From a profitability perspective, hygiene-oriented innovations often carry better unit economics than mainstream tissue, offering a route for margin accretion if scale continues to build. This matters for the current quarter because the lack of a broad margin consensus increases market sensitivity to realized gross spread. If Hygiene Products expands its revenue share and sustains healthy contribution margins, the company could deliver a favorable profit mix that supports adjusted earnings—even though consensus EPS for the quarter is not available.

What matters most for the stock this quarter: Gross-margin trajectory and earnings quality

The single most important driver for the stock into this print is the trajectory of gross margin against last quarter’s 35.47%, as the market lacks clear forecasts for profit ratios and adjusted EPS. With revenue growth projected at only 1.51% YoY (RMB 11.54 billion), valuation sensitivity will hinge on whether cost-of-goods sold efficiency and product mix hold up, allowing the company to defend or expand gross spread. If gross margin trends are stable or better, investors are likely to infer resilience in the 10.32% net profit margin baseline, while any notable compression could prompt concern that incremental revenue is being bought through discounts.

Earnings quality will also be assessed through EBIT consistency and cash conversion. Last quarter’s EBIT of RMB 1.73 billion grew 18.38% YoY, well ahead of revenue, suggesting improved operating leverage and cost controls. A repeat of this pattern—where EBIT growth outpaces revenue growth—would signal continued discipline and efficiency, elevating confidence in the sustainability of profit. Conversely, if EBIT decelerates more than revenue, it would imply either reinvestment or pressure from operating expenses, both of which would temper the near-term profitability outlook.

Finally, investors will parse the composition of revenue between Tissue Products and Hygiene Products to infer mix effects. Strength in Hygiene Products can lift blended margins through premium contributions, whereas a higher mix of promotional tissue volumes could weigh on gross margin. Absent consensus EPS, the market will likely triangulate profitability via reported gross and net margins, the absolute net income line, and commentary on pricing, promotions, and input costs. Delivering another quarter of stable net profit—last reported at RMB 581.00 million with flat quarter-on-quarter momentum—would support the stability narrative, while any deviation from that run rate will frame post-print price action.

Analyst Opinions

Across the previews reviewed in the current window, the stance tilts bullish, focusing on a steady revenue outcome and the prospect of maintained margins; the ratio of bullish to bearish opinions is assessed at 100% to 0% among items surveyed. The dominant view emphasizes a low-single-digit revenue increase to approximately RMB 11.54 billion (+1.51% YoY) and highlights that the absence of formal consensus for gross margin, net margin, and adjusted EPS keeps attention on qualitative indicators such as pricing discipline, input costs, and the mix between Tissue Products and Hygiene Products.

The bullish case centers on three points. First, prior-quarter execution set a constructive base: revenue rose 3.94% YoY to RMB 11.26 billion, while EBIT climbed 18.38% YoY to RMB 1.73 billion, indicating that profit expansion outpaced sales growth. Second, last quarter’s gross margin of 35.47% and net margin of 10.32% offer a buffer if current-quarter top-line growth remains at 1.51% YoY; a stable or slightly better spread could still support healthy earnings quality. Third, the revenue framework for segments suggests that Hygiene Products, at RMB 6.86 billion in the last breakdown, provides an avenue for mix-led resilience, which could mitigate volatility from tissue input costs.

Within this majority perspective, the key validation point for the print is simple: demonstrate that gross margin can be held near last quarter’s level without heavy promotional activity and that net profit remains aligned with the recent RMB 581.00 million run rate. Any indication that pricing and product mix can offset cost fluctuations would underpin a favorable reaction, even in the absence of a detailed EPS consensus. Conversely, the bullish camp acknowledges that if gross margin slips and operating expenses outpace the modest revenue growth, the market may recalibrate expectations quickly; still, the base case remains that steady revenue and disciplined cost management can deliver a serviceable quarter.

Overall, the prevailing opinion anticipates a measured, margin-defended result, with upside if Hygiene Products contributes a higher share of premiumized sales and if Tissue Products benefits from stable input-cost trends and judicious pricing. While published forecasts for EPS are sparse, the consensus anchors around RMB 11.54 billion of revenue and tracks qualitative indicators to gauge profitability. This approach keeps the focus on the defensibility of gross margin, the trajectory of EBIT relative to revenue, and the confirmation that last quarter’s operating improvements can be sustained in the current period.